Safety and efficacy of a novel Prunus domestica extract (Sitoprin, CR002) on testosterone-induced benign prostatic hyperplasia (BPH) in male Wistar rats

References

• Agarwal M, Nahata A, Dixit V. (2012). Protective effects of Echinops echinatus on testosterone-induced prostatic hyperplasia in rats. Eur J Integr Med 4:e177–85
   Google Scholar
• Allkanjari O, Vitalone TC. (2015). What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 126:42–56
   PubMed Web of Science ®Google Scholar
• Ammar AE, Esmat A, Hassona MD, et al. (2015). The effect of pomegranate fruit extract on testosterone-induced BPH in rats. Prostate 75:679–92
   PubMed Web of Science ®Google Scholar
• Bach SM, Perotti ME, Merep AP, et al. (2013). Chemical constituents, anti-inflammatory and antioxidant activities of bark extracts from Prunus tucumanesis Lillo. Nat Prod Res 27:916–19
   PubMed Web of Science ®Google Scholar
• Becker H, Ebeling L. (1988). Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton N. Results of a placebo-controlled double-blind study. Urologe B 28:301–6
   Google Scholar
• Becker H, Ebeling L. (1991). Phytotherapy of benign prostatic hyperplasia (BPH) with Cernilton N. Result of a controlled clinical study. Urologe B 31:113–16
   Google Scholar
• Bourge’s-Abella NH, Reynolds BS, Geffre’ A, et al. (2009). Validation of the Medonic CA620/530 Vet 20-ml microcapillary sampler system for hematology testing of feline blood. J Vet Diagn Invest 21:364–8
   PubMed Web of Science ®Google Scholar
• Braeckman J. (1994). The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Therap Res 56:776–85
   Web of Science ®Google Scholar
• Buck AC, Cox R, Rees RW, et al. (1990). Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract Cernilton. A double-blind, placebo-controlled study. Br J Urol 66:398–404
   PubMedGoogle Scholar
• Buck AC, Rees RW, Ebeling L. (1989). Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 64:496–9
   PubMedGoogle Scholar
• Champault G, Patel JC, Bonnard AM. (1984). A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18:461–2
   PubMed Web of Science ®Google Scholar
• Clive D, McCuen R, Spector JF, et al. (1983). Specific gene mutations in L5178Y cells in culture. Mutat Res 115:225–51
   PubMed Web of Science ®Google Scholar
• Denis LJ. (1996). Editorial review of “Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients”. Prostate 29:241–2
   Web of Science ®Google Scholar
• Di Silverio F, Flammia GP, Sciarra A, et al. (1993). Plant extracts in BPH. Minerva Urol Nefrol 45:143–9
   PubMedGoogle Scholar
• Ebeling L. (1986). The therapeutic results of defined pollen extracts in patients with chronic prostatitis. In Schmiedt E, Aiken JE, Bauer HW, eds. Therapy of prostatitis. Munchen: Zuckschwerdt Verlag, 154–60
   Google Scholar
• Edgar AD, Levin R, Constantinou CE, et al. (2007). A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourol Urodyn 26:458–64
   PubMed Web of Science ®Google Scholar
• Elkelany OO, Owen RC, Kim ED. (2015). Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Ther Clin Risk Manag 11:507–13
   PubMed Web of Science ®Google Scholar
• FDA. (1987). Good laboratory practices (GLP) for non-clinical laboratory studies. In: Department of Health and Human services. Washington, DC: US Food and Drug Administration: 297–310
   Google Scholar
• Fong YK, Milani S, Diavan B. (2005). Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol 15:45–8
   PubMed Web of Science ®Google Scholar
• Gerber GS. (2002). Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 3:285–391
   PubMedGoogle Scholar
• Guo QL, Ding QL, Wu ZQ. (2004). Effect of Baicalein on experimental prostatic hyperplasia in rats and mice. Biol Pharm Bull 27:333–7
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM, Witt TJ. (2014). Lower urinary tract symptoms in men. BMJ 349:g4474. doi: 10.1136/bmj.g4474
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Girman CJ, Guess HA, et al. (1995). New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 155:477–81
   PubMed Web of Science ®Google Scholar
• Leander G. (1962). Preliminary research on the therapeutic effect of Cernilton on chronic prostatovesiculitis. Svenska Lakartidningen 59:3296–304
   PubMedGoogle Scholar
• Lee MY, Shin IS, Seo CS. (2012). Effects of Melandrium firmum methanolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats. Asian J Androl 14:320–4
   PubMed Web of Science ®Google Scholar
• Lytton B, Emery JM, Harvard BM. (1968). The incidence of benign prostatic obstruction. J Urol 99:639–45
   PubMed Web of Science ®Google Scholar
• Maron DM, Ames BN. (1983). Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173–215
   PubMed Web of Science ®Google Scholar
• Nahata A, Dixit VK. (2011). Sphaeranthus indicus attenuates testosterone induced prostatic hyperplasia in albino rats. Phytother Res 25:1839–48
   PubMed Web of Science ®Google Scholar
• Nahata A, Dixit VK. (2012a). Ameliorative effects of Stinging Nettle (Urtica dioica) on testosterone induced prostatic hyperplasia in rats. Andrologia 44:396–409
   PubMed Web of Science ®Google Scholar
• Nahata A, Dixit V. (2012b). Ganoderma lucidum is an inhibitor of testosterone induced prostatic hyperplasia in rats. Andrologia 44:160–74
   PubMed Web of Science ®Google Scholar
• Nandecha C, Nahata A, Dixit V. (2010). Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. Curr Ther Res 71:331–43
   PubMed Web of Science ®Google Scholar
• National Research Council. (2011). Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academies Press
   Google Scholar
• OECD. (1998). Principles of good laboratory practice organization for economic cooperation and development. Paris: Chemicals Group and management Committee
   Google Scholar
• Pagano E, Laudato M, Griffo M, et al. (2014). Phytotherapy of benign prostatic hyperplasia. A mini review. Phytother Res 28:949–55
   PubMed Web of Science ®Google Scholar
• Patel ND, Parsons JK. (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Ind J Urol 30:170–6
   PubMedGoogle Scholar
• Preuss HG, Adderly B. (1998). The prostate cure. New York: Crown Publishers, Inc., 1–251
   Google Scholar
• Preuss HG, Marcusen C, Regan J, et al. (2001). Randomized trial of a combination of natural products (cernitin, saw palmetto, β-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 33:217–25
   PubMedGoogle Scholar
• Rhodes L, Primka RL, Berman C, et al. (1993). Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition. Prostate 22:43–51
   PubMed Web of Science ®Google Scholar
• Shenouda NS, Sakla MS, Newton LG, et al. (2007). Phytosterol Pygeum Africanum regulates prostate cancer in vitro and in vivo. Endocrine 31:72–81
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Gupta VB. (2012). Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health 3:10–19
   PubMedGoogle Scholar
• Stenger A, Tarayre JP, Carilla E. (1982). Etude pharmacologique et biochimique de l’extrait hexanique de serenoa repens. B: Gaz Med de France 89:2041–8
   Google Scholar
• Stoner E. (1990). The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 37:375–8
   PubMed Web of Science ®Google Scholar
• Stoner E. (1996). 5 Alpha-reductase inhibitors/finasteride. Prostate Suppl 6:82–7
   PubMedGoogle Scholar
• Sultan C, Terraza A, Devillier C, et al. (1984). Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 20:515–19
   PubMedGoogle Scholar
• Talpur N, Echard B, Bagchi D, et al. (2003). Comparison of saw palmetto (extract and whole berry) and cernitin on prostate growth in rats. Mol Cell Biochem 250:21–6
   PubMed Web of Science ®Google Scholar
• Traish AM, Mulgaonkar A, Giordano N. (2014). The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high gleason grade prostate cancer and depression. Korean J Urol 55:367–79
   PubMedGoogle Scholar
• Vikram A, Jena G, Ramarao P. (2010). Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 641:75–81
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Howe W, MacDonald R. (2002). Terazosin for treating symptomatic benign prostatic obstruction: a systematic review and efficacy and adverse effects. BJU Int 89:214–25
   PubMed Web of Science ®Google Scholar
• Wise GJ, Md EO. (2001). Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep 2:285–91
   PubMedGoogle Scholar
• Wright S, Thomas LN, Douglas RC, et al. (1996). Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of castrated rat. J Clin Invest 98:2558–63
   PubMed Web of Science ®Google Scholar
• Yasumoto R, Kawanishi H, Tsujino T, et al. (1995). Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther 17:82–7
   PubMed Web of Science ®Google Scholar
• Zhong X, Lin J, Zhou J, et al. (2015). Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo. Mol Med Rep 12:1699–708
   PubMed Web of Science ®Google Scholar